Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Zenas BioPharma Q3 2026 Results: Net Loss of $109M, Loss Widens

Zenas BioPharma, Inc. reported a significant increase in liquidity as of September 30, 2026, with cash, cash equivalents, and short-term investments totaling approximately $585.3 million, up from $343.2 million at the end of 2025. The company continues to operate as a non-accelerated filer and emerging growth company, focusing on the development of product candidates for immunology and inflammation diseases.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10.0—
Profit before tax-108.9-51.5
Net income-108.9-51.5
EPS (diluted, $ a share)$-1.65$-1.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ZBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Zenas BioPharma, Inc.: key numbers

Share price
$27.93Close, Nov 16
Market cap
$1.89B
Shares outstanding
67.82MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Zenas BioPharma, Inc.

All →
4:16 PM ET 8-K
Capital Raise

Zenas BioPharma Capital Raise

Zenas BioPharma filed a new prospectus supplement to increase its at-the-market (ATM) offering program capacity by $200 million. This replaces a prior supplement under which the company had already sold approximately $153.2 million in common stock, leaving $46.8 million unsold from the previous authorization.

Counterparty
Jefferies LLC
7:13 AM ET 8-K
Financial Results

Zenas BioPharma Financial Results

Zenas BioPharma reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of its BLA for obexelimab with a PDUFA date of May 27, 2027. The company ended the quarter with $647.1 million in cash and investments, which it expects will fund operations into 2027 as it prepares for potential commercialization.

Term
Q3 2026

“This quarter we continued to execute across our portfolio as we prepare for the potential commercialization of obexelimab for the treatment of IgG4-RD. Following the FDA’s acceptance of our BLA in the second quarter of this year, and the recent submission of our MAA to the EMA, we remain focused on commercial readiness ahead of the potential launch.”

Lonnie Moulder, Founder and Chief Executive Officer

“Across our broader pipeline, we remain on track to report topline Phase 2 SunStone data in SLE and initial Phase 1 data for our oral IL-17 inhibitor, ZB021, this quarter. We look forward to closing out a very productive year as we turn our attention to 2027 and continue to build toward our vision of becoming a fully integrated, global development and commercial-stage biopharmaceutical company.”

Lonnie Moulder, Founder and Chief Executive Officer
6:03 AM ET 8-K
Clinical Trial Data

Zenas BioPharma Clinical Trial Data

Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.